Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 208-048-6 | CAS number: 506-64-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 21 March 2014 to 25 April 2014
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP compliant, guideline study, available as an unpublished report.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 014
- Report date:
- 2014
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 425 (Acute Oral Toxicity: Up-and-Down Procedure)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- up-and-down procedure
- Limit test:
- no
Test material
- Reference substance name:
- Silver cyanide
- EC Number:
- 208-048-6
- EC Name:
- Silver cyanide
- Cas Number:
- 506-64-9
- Molecular formula:
- CAgN
- IUPAC Name:
- silver(1+) cyanide
- Test material form:
- solid: particulate/powder
- Remarks:
- migrated information: powder
- Details on test material:
- - Name of test material: Silver cyanide
- CAS number: 506-64-9
- Substance type: White powder
- Physical state: Solid
- Date of manufacture: June 2013
- Stability under test conditions: Stable under standard conditions.
- Storage condition of test material: Store in room temperature in a tightly closed container.
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: CD/Crl: CD(SD)
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Research Models and Services, Germany GmbH, Sandhofer Weg 7, 97633 Sulzfeld, DE
- Age at study initiation: approximately 8 weeks
- Weight at study initiation: 175 - 192 g
- Fasting period before study: 16 hours before administration of the test item.
- Housing: the animals were kept individually in MAKROLON cages (type III plus) at a room tepmerature of 22 ± 3 °C and a relative humidity of 55 ± 15 %. The rooms were lit (150 lux at appoximately 1.5 m room height) and darkened for periods of 12 hours each.
- Diet: Commercial ssniff (R) R/M-H V1534 (ssniff Spezialdiäten GmbH, 59494 Soest, DE)
- Water: ad libitum
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3 °C
- Humidity (%): 55 ± 15 %
- Air changes (per hr): not reported
- Photoperiod (hrs dark / hrs light): 12 h of darkness / 12 h of light
IN-LIFE DATES: From: 21 March 2013 To: 25 April 2014
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: 1 % aqueous hydroxypropylmethylcellulose
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: The test item was suspended in 1 % aqueous hydroxypropylmethylcellulose. The doses were 55, 175 and 550 mg silver cyanide/kg bodyweight.
- Amount of vehicle (if gavage): 20 mL/kg bodyweight
- Justification for choice of vehicle: Not reported
- Lot/batch no. (if required): Not reported.
- Purity: Not reported.
MAXIMUM DOSE VOLUME APPLIED: 20 mL/ kg bodyweight, maximum administration volume was 3.8 mL/rat
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: Available data indicated an LD50 of 123 mg/kg in rats. - Doses:
- Dosing was initiated at 55 mg/kg bw and continued using a progrssion factor of approximately 3.2. The resulting sequence was 55, 175, 55, 175, 550, 175, 550 and 175 mg/kg bw. Each dose level was conducted with one female rat.
- No. of animals per sex per dose:
- 2 female rats at 55 mg/kg bw
4 female rats at 175 mg.kg bw
2 female rats at 550 mg/kg bw - Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing:Observations were performed before dosing, during dosing, at 5, 15, 30 and 60 minutes and 3, 4, 6 and 24 hours after administration. all surviving animals were observed for a period of 14 days. Individual body weights were recorded before administration of the test item and thereafter in weekly intervals up to the end of the study and at death. Changes in weight were calculated if survival exceeds one day.
- Necropsy of survivors performed: yes
- Other examinations performed: changes of skin and fur, eyes and mucous membranes, respiratory and circulatory function, autonomic and central nervous
system and somatomotor activity, as well as behaviour pattern, were observed at least once a day until all symptoms subsided, thereafter each working day. Attention was also paid to possible tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma. Observations on mortality were made at least once daily to minimize loss of animals during the study. - Statistics:
- The LD50 was calculated using the method of maximum likelihood.
Results and discussion
- Preliminary study:
- Available information indicated an LD50 of 123 mg/kg in rats. Thus, the Limit Test could be omitted and the study started with the Main Test.
Effect levels
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 175 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 62.5 - 487
- Remarks on result:
- other: by oral administration
- Mortality:
- A single oral administration of 55 mg/kg bw resulted in no premature deaths. Two of four animals died after dosing with 175 mg/kg bw and two of two animals died after dosing with 550 mg/kg bw.
- Clinical signs:
- other: At 55 mg/kg bw clinical observations included reduced motility, ataxia, tremor, reduced muscle tone, dyspnoea and pilo-erection in 2 of 2 female animals, tonic convulsions and ptosis in 1 animal. All clinical signs had resolved within 24 hours of dosing.
- Gross pathology:
- No signs or abnormalities observed.
- Other findings:
- Not reported.
Any other information on results incl. tables
Table 1. Summarised results
Symptoms/criteria |
55 mg/kg (n=2) females |
175 mg/kg (n=4) females |
550 mg/kg bw (n=2) females |
Mortality 6 h 24 h 7 d 14 d |
0 0 0 0 |
1 2 2 2 |
2 2 2 2 |
Mean body weight (g) Start |
178.5 |
185.0 |
190.0 |
After 7 d |
217.5 (+21.8) |
204.5 (+10.5) |
ƚ |
After 14 d |
230.5 (+29.1) |
221.5 (+19.7) |
|
Inhibition of body weight gain |
none |
none |
ƚ |
Necropsy findings |
none |
none |
none |
Applicant's summary and conclusion
- Interpretation of results:
- Toxicity Category III
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- The acute lethat dose (LD50) of silver cyanide in the female rat was estimated to be 175 mg/kg bodyweight.
- Executive summary:
Introduction
The study was performed to assess the acute oral toxicity of silver cyanide in rats. The study was conducted according to GLP and OECD 425 guideline.
Methods
Female rats were dosed with silver cyanide by oral gavage. Dosing was initiated at 55 mg/kg bw and continued using a progression factor of approximately 3.2 according to up-and-down procedure. The resulting sequence was 55, 175, 55, 175, 550, 175, 550 and 175 mg/kg bw. Each dose level wass conducted with one female rat. Following administration, observations were made and recorded systematically with individual records being maintained for each animal. Observations were performed before dosing, during dosing and 5, 15, 30 and 60 minutes and 3, 4, 6 and 24 hours after administration. All surviving animals were observed for a period of 14 days.
Results
Mortality
A single oral administration of 55 mg/kg bw resulted in no premature deaths. Two of four animals died after dosing with 175 mg/kg bw and two of two animals died after dosing with 550 mg/kg bw.
Clinical signs
Clinical observations at 55 mg/kg bw included reduced motility, ataxia, tremor, reduced muscle tone, dyspnoea and pilo-erection in 2 of 2 female animals, tonic convulsions and ptosis in 1 animal. All clinical signs had resolved within 24 hours of dosing. Reduced motility, ataxia, tremor, reduced muscle tone, dyspnoea and pilo-erection in 4 of 4 female animals, and tonic convulsions, STRAUB tail, ptosis and mydriasis in 2 animals were observed at 175 mg/kg bw. Abnormal abdominal position and abnormal dorsal position were noted in one animal which died prematurely. In the surviving two animals all clinical signs had resolved within 24 hours of dosing. At 550 mg/kg bw clinical observations were reduced motility, ataxia and dyspnoea in 2 of 2 female animals, tremor, reduced muscle tone, tonic convulsions, pilo-erection, ptosis and abnormal dorsal position in 1 animal.
Bodyweight
All animals gained the expected body weight.
Necropsy
No sings or abnormalities were observed at necropsy.
Conclusion
The acute lethal dose (LD50) of silver cyanide in the female rat was estimated to be 175 mg/kg bodyweight with 95 % confidence intervals of 62.5 to 487 mg/kg bw.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.